INmune Bio (INMB) sets out Ebstrocel's next UK regulatory steps
A preparatory submission moves the programme forward, while the full application remains targeted for February.
Get analysis like this in your inbox.
Join investors and analysts following Lex Commentary.
INmune Bio said it submitted its final pre-marketing-authorisation package to the UK medicines regulator on 20 October for Ebstrocel, its investigational cell therapy for recessive dystrophic epidermolysis bullosa.
The company is targeting a full marketing-authorisation application in early February 2027 and a US biologics application in the second quarter. It believes the revised UK strategy could bring potential approval forward by about six weeks.
Those dates are company expectations. A pre-application package is distinct from a completed marketing application, and neither establishes that regulators have accepted the evidence as sufficient for approval. Ebstrocel remains investigational.
The update provides a clearer sequence of milestones for a programme addressing a serious rare skin disorder. The investment question now centres on whether the company can complete the application and support its clinical and manufacturing case through review. A more defined timetable helps investors follow progress, but the eventual decision will turn on the submitted evidence rather than the projected calendar.